Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.
Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on epilepsy treatments, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 11:00 a.m. ET. Management aims to highlight their innovative therapies and ongoing research.
An archived replay of the presentation will be available on their website post-event. Ovid's pipeline includes OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures, and OV350, targeting epilepsies. Additionally, Ovid is significantly involved in the soticlestat development, currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes, managed by Takeda. For further information about Ovid's initiatives, visit ovidrx.com.
Ovid Therapeutics (NASDAQ: OVID) provided a business update and 2022 financial results, indicating a cash runway into H1 2025. The company reported a revenue of $1.5 million for 2022, a significant decline from $208.4 million in 2021. This decline was due to a one-time payment from Takeda in 2021. Ovid continues to advance its potential next-generation GABA-aminotransferase inhibitor, OV329, which is undergoing a Phase 1 trial, with results expected in H1 2024. Ovid also highlights ongoing collaborations and cost-cutting measures that have helped reduce operating expenses. The company posted a net loss of $54.2 million for 2022, compared to a net income of $122.8 million in 2021.
Ovid Therapeutics Inc. (NASDAQ: OVID) announced its participation in a fireside chat during the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023, at 4:00 p.m. ET. Investors can access a live webcast of the event via the company’s website, with an archived replay available afterward. Ovid focuses on developing medicines for epilepsies and brain disorders, with notable programs including OV329, aimed at treatment-resistant seizures, and OV350, intended for potential epilepsy treatment. The company also has significant interest in soticlestat, currently in Phase 3 trials targeting Dravet and Lennox-Gastaut syndromes.
Ovid Therapeutics (NASDAQ: OVID) has published findings regarding its compound OV350 in Cell Reports Medicine, highlighting its potential in treating treatment-resistant epilepsies. OV350 directly activates the KCC2 co-transporter, reducing neuronal hyperexcitability and intracellular chloride accumulation. Preclinical studies reveal that OV350 can arrest benzodiazepine-resistant seizures, restore efficacy of benzodiazepines, and reduce neuronal injury following status epilepticus. The compound was found to penetrate the brain effectively without causing sedation. Ovid aims to explore various modes of delivery for OV350 and other KCC2 activators.
Ovid Therapeutics Inc. (NASDAQ: OVID) announced participation in a panel titled “Orphan Epilepsies” at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 12:50 p.m. ET in Boston, Massachusetts. A live webcast will be available on their website, with an archived replay following the event.
Ovid specializes in biopharmaceuticals aimed at treating epilepsies and brain disorders. Their development pipeline includes OV329 for treatment-resistant seizures and OV350 targeting the KCC2 transporter. They also hold a financial interest in soticlestat, currently in Phase 3 trials, which is being developed by Takeda.